Accelerating Breakthrough Discoveries into Medicines

Amy Trainor

Amy Trainor, PhD

Amy Trainor.jpg

Dr. Trainor has extensive experience in global pharmaceutical drug discovery and development. She has leadership expertise in overall drug development strategy and execution, discovery with an emphasis on medicinal chemistry, and development of global external partnerships. She has broad leadership experience with in-licensing with an emphasis on due diligence, product development strategy and planning, and creative partnering strategies. .

Dr. Trainor joins BioMotiv after 30 years at AstraZeneca Pharmaceuticals and two years as a consultant. Her most recent role at AstraZeneca was Neuroscience Global External Partnerships Director. In this role she created an alliance strategy resulting in a portfolio of collaborations focused on providing complementary drug discovery and development capabilities. These alliances focused on partnerships with key academic centers, institutes, disease foundations, and government agencies. At that time she was also a senior member of the Neuroscience leadership team responsible for the strategic development and execution of a Neuroscience late discovery and early development portfolio. Prior to her role in external partnerships she was Global Project Director at AstraZeneca for multiple global product teams in Oncology and Neuroscience. In that role she was responsible for candidate nomination through delivery to end of Phase II including leading teams responsible for Iressa, Zibotetan and Recentin.

She is an inventor on 20 issued US patents and is an author on multiple peer-reviewed publications. Dr. Trainor did her undergraduate work at Stevens Institute of Technology, received her PhD in Bioorganic Chemistry at Brandeis University and was an NIH Postdoctoral Fellow at Columbia University.